Skip to content

Cellectar Biosciences, Inc.: stockholders equity

Stockholders equity for Cellectar Biosciences, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.

All Cellectar Biosciences, Inc. financial histories

What this measure means

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Exact concept: us-gaap:StockholdersEquity. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2002-11-06 to 2025-12-31. The SEC response was captured on 2026-09-20.

Selected filing history

Stockholders equity in original reported units, latest-filed observation per period
Period startPeriod endValueUnitFiledSource filing
At date2025-12-318,537,164USD2026-03-0410-K · 0001104659-26-023167
At date2024-12-3114,294,681USD2026-03-0410-K · 0001104659-26-023167
At date2023-12-31-15,158,968USD2026-03-0410-K · 0001104659-26-023167
At date2023-09-30-28,000,262USD2024-10-2910-K/A · 0001410578-24-001704
At date2023-06-30-8,387,900USD2024-10-2910-K/A · 0001410578-24-001704
At date2023-03-311,370,983USD2024-10-2910-K/A · 0001410578-24-001704
At date2022-12-318,153,244USD2025-03-1310-K · 0001410578-25-000329
At date2022-09-3010,768,486USD2024-10-2910-K/A · 0001410578-24-001704
At date2022-06-3017,912,049USD2024-10-2910-K/A · 0001410578-24-001704
At date2022-03-3123,127,139USD2024-10-2910-K/A · 0001410578-24-001704
At date2021-12-3129,063,131USD2024-10-2910-K/A · 0001410578-24-001704
At date2020-12-3154,794,529USD2023-03-0910-K · 0001410578-23-000224
At date2019-12-319,059,409USD2022-03-2110-K · 0001410578-22-000436
At date2018-12-3113,260,961USD2021-03-0210-K · 0001104659-21-030445
At date2017-12-3110,754,463USD2020-03-0910-K · 0001104659-20-030742
At date2016-12-3113,539,872USD2019-02-2610-K · 0001144204-19-009973
At date2015-12-311,649,803USD2018-03-2110-K · 0001144204-18-016175
At date2014-12-316,697,533USD2017-03-1510-K · 0001144204-17-014611
At date2013-12-311,699,550USD2016-10-2010-K/A · 0001144204-16-128786
At date2012-12-3110,158,375USD2015-05-2010-K · 0001144204-15-032559
At date2011-12-319,481,123USD2014-03-1910-K · 0001144204-14-016712
At date2010-12-31133,762USD2014-03-1910-K · 0001144204-14-016712
At date2009-12-314,126,893USD2014-03-1910-K · 0001144204-14-016712
At date2008-12-319,844,567USD2014-03-1910-K · 0001144204-14-016712
At date2007-12-312,526,232USD2014-03-1910-K · 0001144204-14-016712
At date2006-12-316,546,165USD2014-03-1910-K · 0001144204-14-016712
At date2005-12-31400,206USD2014-03-1910-K · 0001144204-14-016712
At date2004-12-3146,175USD2014-03-1910-K · 0001144204-14-016712
At date2003-12-31388,936USD2014-03-1910-K · 0001144204-14-016712
At date2002-12-31599,377USD2014-03-1910-K · 0001144204-14-016712
At date2002-11-060USD2014-03-1910-K · 0001144204-14-016712

Related financial histories

Inspect the source

Entity
Cellectar Biosciences, Inc. / CIK 0001279704
Captured
2026-09-20T07:48:31.991Z
SEC response SHA-256
44da00fed89c835867d9290b98319109f07ad849957763fd081353f99891a212

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001279704.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))